James David Marks MD
Critical Care Medicine
Professor, Anesthesia & Perioperative Care, UCSF School of Medicine
Join to View Full Profile
1001 Potrero AveRm 3c34San Francisco, CA 94110
Phone+1 415-206-8934
Fax+1 415-206-3101
Dr. Marks is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Anesthesiology, 1984 - 1986- University of California (San Francisco)Fellowship, Critical Care Medicine (Anesthesiology), 1982 - 1983
- University of California (San Francisco)Residency, Internal Medicine, 1979 - 1982
- University of California San Francisco School of MedicineClass of 1979
Certifications & Licensure
CA State Medical License 1980 - 2026
American Board of Anesthesiology Anesthesiology- American Board of Anesthesiology Critical Care Medicine
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 2006
Publications & Presentations
PubMed
- 5 citationsDynamic allostery drives autocrine and paracrine TGF-β signaling.Mingliang Jin, Robert I Seed, Guoqing Cai, Tiffany Shing, Li Wang
Cell. 2024-10-31 - 2 citationsSan Francisco's Citywide COVID-19 Response: Strategies to Reduce COVID-19 Severity and Health Disparities, March 2020 Through May 2022.Darpun D Sachdev, Maya Petersen, Diane V Havlir, Joshua Schwab, Wayne T A Enanoria
Public Health Reports. 2023-07-05 - 5 citationsA Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice.Yongfeng Fan, Jianlong Lou, Christina C Tam, Weihua Wen, Fraser Conrad
Toxins. 2023-04-30
Grant Support
- Evolving Diagnostic Antibodies For Botulinum NeurotoxinsNational Institute Of Allergy And Infectious Diseases2011–2012
- Development Of Botulinum Neurotoxin Immunotherapy, Serotypes C, D, F, And GNational Institute Of Allergy And Infectious Diseases2007–2011
- Using Mass Spec To Determine Molecular Identity Of Tumor Specific AntigenNational Center For Research Resources2004–2011
- Design And Generation Of Cross- Reactive Botulinum Neurotoxin AntibodiesNational Institute Of Allergy And Infectious Diseases2009–2010
- Development Of Botulinum Neurotoxin ImmunotherapyNational Institute Of Allergy And Infectious Diseases2003–2007
- Deciphering Toxin Neutralization By Oligoclonal AntibodyNational Institute Of Allergy And Infectious Diseases2002–2003
- Phage Antibody Based Probes Of ERBB Receptor FunctionNational Cancer Institute2001–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
